USE OF PROSTAGLANDIN E2 (PGE2)-PRIMED MESENCHYMAL STEM CELL (MSC) PRODUCT IN PREPARATION OF DRUG FOR TREATING LUNG INJURY (LI)
The present disclosure relates to the technical field of medicine, in particular to use of a prostaglandin E2 (PGE2)-primed mesenchymal stem cell (MSC) product in preparation of a drug for treating lung injury (LI). A preparation method of the PGE2-primed MSC product includes conducting mixed culture on PGE2 and MSCs to obtain the PGE2-primed MSC product. The PGE2 and the MSCs are subjected to the mixed culture to enhance functions of the MSCs, promote migration of the MSCs to injury sites, strengthen anti-inflammatory effects of the MSCs, facilitate MSC proliferation, effectively relieve various lung injuries, and accelerate regeneration of injured alveolar epithelial cells. The drug prepared from the PGE2-primed MSC product provided by the present disclosure can effectively relieve LI and accelerate the regeneration of injured alveolar epithelial cells, and a remarkable treatment effect is obtained..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 28. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LI ZONGJIN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-28, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
US2023414667 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019021526 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019021526 | ||
| 003 | DE-627 | ||
| 005 | 20240209083238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019021526 | ||
| 035 | |a (EPA)US2023414667 | ||
| 035 | |a (EPA)82626586 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LI ZONGJIN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a USE OF PROSTAGLANDIN E2 (PGE2)-PRIMED MESENCHYMAL STEM CELL (MSC) PRODUCT IN PREPARATION OF DRUG FOR TREATING LUNG INJURY (LI) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-28, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09 | ||
| 520 | |a The present disclosure relates to the technical field of medicine, in particular to use of a prostaglandin E2 (PGE2)-primed mesenchymal stem cell (MSC) product in preparation of a drug for treating lung injury (LI). A preparation method of the PGE2-primed MSC product includes conducting mixed culture on PGE2 and MSCs to obtain the PGE2-primed MSC product. The PGE2 and the MSCs are subjected to the mixed culture to enhance functions of the MSCs, promote migration of the MSCs to injury sites, strengthen anti-inflammatory effects of the MSCs, facilitate MSC proliferation, effectively relieve various lung injuries, and accelerate regeneration of injured alveolar epithelial cells. The drug prepared from the PGE2-primed MSC product provided by the present disclosure can effectively relieve LI and accelerate the regeneration of injured alveolar epithelial cells, and a remarkable treatment effect is obtained. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CHAI ZIHAN |4 aut | |
| 700 | 0 | |a WANG CHEN |4 aut | |
| 700 | 0 | |a HEZAM KAMAL |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 28. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:28 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/82626586/publication/US2023414667A1?q=US2023414667 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 28 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 28 |c 12 | ||